RHOA and posterior cortical atrophy: In addition, treatment with Simvastatin, a RhoA subfamily Rho GTPase inhibitor, significantly increased the levels of phosphorylated LATS1 and YAP1 and reduced the nuclear levels of YAP1 in MYBL2-overexpressing PCa cells (Figure 6A-B).